Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus NAQUA.
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering blood pressure.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
1 tablet (candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: 1 tablet (32 mg/25 mg) once daily.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Candesartan: Terminal t1/2 ~9 hours (linear); clinically, once-daily dosing provides 24-hour antihypertensive effect. Hydrochlorothiazide: Terminal t1/2 ~6-15 hours (averaging 10 hours), prolonged in renal impairment.
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Candesartan: ~33% renal, ~67% biliary/fecal as unchanged drug and inactive metabolites. Hydrochlorothiazide: ≥95% renal as unchanged drug.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic